Loading...

What is a clinical trial?

Clinical trials are research studies conducted with people affected by HAE to evaluate whether a drug is safe and effective in humans. They are one of the final stages of the medical research and development process and follow strict standards to protect people. Clinical trials for investigational drugs typically go through three phases before Health Canada reviews and approves them.

Phase 1

Typically conducted with a small group, phase one trials help researchers understand the safety & tolerability of an investigational drug.

Phase 2

In phase two, researchers further test the safety and efficacy of a medicine as well as the correct dosages and effectiveness.

Phase 3

Typically conducted in a larger group, in phase three researchers assess the safety and potential effectiveness of a medicine.

Clinical trials are an essential part of drug development and are required to be conducted in Canada before a treatment can be approved by Health Canada and become available by prescription. If you are interested in participating in a trial, please contact a trial site to discover if you are eligible. If you do not live near a site, please contact either HAE Canada (office@haecanada.org) or the clinic directly for details about sponsored travel opportunities.

ALPHA-STAR Trial: STAR-0215

Astria Therapeutics

Recruiting

Ottawa, ON

Edmonton

HAE Type I & II

Adults 18 yrs +

Subcutaneous Prophylactic

STAR-0215

Trial & Treatment Details

ClinicalTrials.gov

Berotralstat (ORLADEYO)

BioCryst Pharmaceuticals

Recruiting

Ottawa, ON

HAE Type I & II

Children 2-12 yrs

Oral Prophylactic

Berotralstat (ORLADEYO)

Trial & Treatment Details

ClinicalTrials.gov

CSL – 312 (Garadacimab)

CSL Behring

Recruiting

Ottawa, ON

HAE Types I & II

Children 2-11 yrs

Subcutaneous Prophylactic

Garadacimab

Trial & Treatment Details

ClinicalTrials.gov

An Observational Study:

PROSPECT Study:

To review the Treatment and Outcomes of HAE patients with Normal C1-INH in Canada

Takeda

Recruiting

Edmonton, AB

Calgary, AB

Hamilton, ON

Québec City, QC

coming soon: Winnipeg

HAE with normal C1-INH

Patients 12 yrs+

Treatment & Trail Details

ClinicalTrials.gov

CSL – 312 (Garadacimab)

CSL Behring

Active, not recruiting

HAE Type I & II

12 years +

Subcutaneous Prophylactic

CSL-312 (Garadacimab)

Treatment & Trail Details

ClinicalTrials.gov

KONFIDENT Study: Sebetralstat (KVD-900)

KalVista Pharmaceuticals

Actve, not recruiting

HAE Type I & II

12 years +

Oral On Demand

Sebetralstat (KVD-900)

Treatment & Trail Details

ClinicalTrials.gov

HAE CHAPTER-1 Study: PHV-S416

Pharvaris

Active, not recruiting

HAE Type I & II

18 – 75 years

Oral Prophylactic

PHVS-416

Treatment & Trail Details

ClinicalTrials.gov

Berotralstat (ORLADEYO)

BioCryst Pharmaceuticals

Recently Completed

HAE Type I & II

12 years +

Oral Prophylactic

Berotralstat (ORLADEYO)

Treatment & Trail Details

ClinicalTrials.gov

CSL-312 (Garadacimab)

CSL Behring

Recently Completed

HAE Type I & II

12 years +

Subcutanious Prophylactic

CSL-312 (Garadacimab)

Treatment & Trail Details

ClinicalTrials.gov

RAPIDe-1 Study: PHVS416

Pharvaris

Recently Completed

HAE Type I & II

18 years +

Oral On Demand

PHVS416

Treatment & Trail Details

ClinicalTrials.gov

EMPOWER Study: Lanadelumab (TAKHZYRO)

Takeda

Recently Completed

HAE Type I & II

All Ages

Subcutanious Prophylactic

Lanadelumab (TAKHZYRO)

Treatment & Trail Details

ClinicalTrials.gov

Lanadelumab (TAKHZYRO)

Takeda

Recently Completed

HAE with Normal C1-INH

12 years +

Subcutanious Prophylactic

Lanadelumab (TAKHZYRO)

Treatment & Trail Details

ClinicalTrials.gov

Updated: June 2023